| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRKAR2B |
| Uniprot No | P31323 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-418 aa |
| 活性数据 | SIEIPAGLT ELLQGFTVEV LRHQPADLLE FALQHFTRLQ QENERKGTAR FGHEGRTWGD LGAAAGGGTP SKGVNFAEEP MQSDSEDGEE EEAAPADAGA FNAPVINRFT RRASVCAEAY NPDEEEDDAE SRIIHPKTDD QRNRLQEACK DILLFKNLDP EQMSQVLDAM FEKLVKDGEH VIDQGDDGDN FYVIDRGTFD IYVKCDGVGR CVGNYDNRGS FGELALMYNT PRAATITATS PGALWGLDRV TFRRIIVKNN AKKRKMYESF IESLPFLKSL EFSERLKVVD VIGTKVYNDG EQIIAQGDSA DSFFIVESGE VKITMKRKGK SEVEENGAVE IARCSRGQYF GELALVTNKP RAASAHAIGT VKCLAMDVQA FERLLGPCME IMKRNIATYE EQLVALFGTN MDIVEPTA |
| 分子量 | 46.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **Title:** "PRKAR2B promotes colorectal cancer cell proliferation and inhibits apoptosis via the PI3K/AKT signaling pathway"
**Authors:** Li X, Wang Y, Zhang Y, et al.
**Summary:** 研究揭示了PRKAR2B通过激活PI3K/AKT通路促进结直肠癌细胞增殖并抑制凋亡，提示其作为癌症治疗潜在靶点。
2. **Title:** "Role of PRKAR2B in Alzheimer’s disease pathogenesis through regulation of amyloid-beta metabolism"
**Authors:** Smith J, Doe A, Brown K.
**Summary:** 发现PRKAR2B表达下调与阿尔茨海默病患者脑内β-淀粉样蛋白异常沉积相关，可能通过调节cAMP信号参与神经退行性变。
3. **Title:** "PRKAR2B deficiency enhances thermogenesis in adipose tissue via PKA-mediated lipolysis"
**Authors:** Chen L, Zhang H, Liu M, et al.
**Summary:** 在小鼠模型中，PRKAR2B缺失通过PKA依赖的脂肪分解途径增加产热，表明其在代谢调控和肥胖治疗中的潜在作用。
4. **Title:** "PRKAR2B as a novel biomarker for early-stage hepatocellular carcinoma diagnosis"
**Authors:** Kim S, Park JH, Lee WJ.
**Summary:** 研究证实血清PRKAR2B水平可作为肝癌早期诊断的生物标志物，其过表达与肝癌患者预后不良相关。
(注：上述文献为模拟示例，实际需查询具体数据库如PubMed获取真实研究。)
PRKAR2B (Protein Kinase cAMP-Dependent Type II Regulatory Subunit Beta) is a regulatory subunit of the cAMP-dependent protein kinase A (PKA), a critical enzyme in cellular signaling pathways. PKA exists as a tetramer composed of two regulatory subunits and two catalytic subunits. PRKAR2B, encoded by the *PRKAR2B* gene, belongs to the type II regulatory subunit family (RII), which includes RIIα (PRKAR2A) and RIIβ (PRKAR2B), alongside the type I subunits (RIα, RIβ). These regulatory subunits differentially control PKA’s subcellular localization, activation, and substrate specificity in response to cyclic AMP (cAMP) signaling.
PRKAR2B is widely expressed, with higher levels detected in adipose tissue, brain, and reproductive organs. It plays roles in lipid metabolism, neuronal signaling, and cell differentiation. Unlike RIIα, RIIβ exhibits tissue-specific expression and distinct biochemical properties, including altered cAMP binding affinity. Its interaction with A-kinase anchoring proteins (AKAPs) helps compartmentalize PKA signaling to specific cellular regions.
Dysregulation of PRKAR2B has been linked to metabolic disorders, obesity, and cancer. For instance, altered RIIβ expression affects adipogenesis and insulin sensitivity. In oncology, PRKAR2B overexpression correlates with tumor progression in certain cancers. Genetic variations in *PRKAR2B* are also associated with neurological conditions like Parkinson’s disease. Research continues to explore its therapeutic potential, particularly in modulating PKA activity for metabolic or neurodegenerative diseases. However, precise mechanistic insights remain limited, warranting further functional studies.
×
